°ÄÃÅÁùºÏ²Ê¿ª½±¼Ç¼

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information.

Advances and Progress in Drug Design

15 - 16 February 2016, London, United Kingdom


Introduction
Hosted over two days, this international conference will provide an exclusive opportunity to gain new insight on small molecule-protein fragments, IMI Open PHACTS project for data mining work flows, and structure-based models combining hit finding strategies of fragment leads.
Inspiring talks will also highlight developments in the quality control of misfolded proteins, solvent effects, and protein-ligand stability; identifying whether the bound conformation of protein-ligand structure gives the lowest energy state and the impact of drug design.

Join us for a keynote address on reviving covalent drug design in oncology from Pfizer, and a case study session on target validation of NCE’s through fragment screening and opportunities for antibodies as guidance tools from UCB.

To register/for more information visit: www.drug-design.co.uk/rscorg
Speakers
  • Gregg Seigal, Chief Executive Officer ZoBio, United Kingdom
  • Doug Johnson, Research Fellow Pfizer, United States
  • Herman van Vlijmen, Senior Director Janssen, Belgium
  • Amin Ruf, Sectin Head, Biostructure Roche, Switzerland
  • Giani Chessari, Director Astex Pharmaceuticals, United Kingdom
  • Manuel Francisco Molina-Martin, Research Scientist Eli Lilly, Spain
  • Howard Feldma, Principal Scientist Chemical Computing Group, United Kingdom

Venue
Holiday Inn Kesington Forum, London, UK

Holiday Inn Kesington Forum, London, UK, 97 Cromwell Rd, London, SW7 4DN, United Kingdom

Organised by
SMi Group Ltd
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*